These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 22059643)

  • 1. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.
    Scarpa M; Almássy Z; Beck M; Bodamer O; Bruce IA; De Meirleir L; Guffon N; Guillén-Navarro E; Hensman P; Jones S; Kamin W; Kampmann C; Lampe C; Lavery CA; Teles EL; Link B; Lund AM; Malm G; Pitz S; Rothera M; Stewart C; Tylki-Szymańska A; van der Ploeg A; Walker R; Zeman J; Wraith JE;
    Orphanet J Rare Dis; 2011 Nov; 6():72. PubMed ID: 22059643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis and management of mucopolysaccharidosis type II.
    Mao SJ; Chen QQ; Dai YL; Dong GP; Zou CC
    Ital J Pediatr; 2024 Oct; 50(1):207. PubMed ID: 39380047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
    Horgan C; Jones SA; Bigger BW; Wynn R
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of children with Hunter syndrome - a case study.
    Little C; Gould R; Hendriksz C
    Br J Nurs; 2009 Mar 12-25; 18(5):321-2. PubMed ID: 19273994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.
    D'Avanzo F; Rigon L; Zanetti A; Tomanin R
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and Gene Therapy in Hunter Disease.
    Sestito S; Falvo F; Scozzafava C; Apa R; Pensabene L; Bonapace G; Moricca MT; Concolino D
    Curr Gene Ther; 2018; 18(2):90-95. PubMed ID: 29618310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.
    Burton BK; Giugliani R
    Eur J Pediatr; 2012 Apr; 171(4):631-9. PubMed ID: 22383073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States.
    Ream MA; Lam WKK; Grosse SD; Ojodu J; Jones E; Prosser LA; Rosé AM; Comeau AM; Tanksley S; Powell CM; Kemper AR
    Genet Med; 2023 Feb; 25(2):100330. PubMed ID: 36445366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience.
    Ceravolo F; Mascaro I; Sestito S; Pascale E; Lauricella A; Dizione E; Concolino D
    Ital J Pediatr; 2013 Sep; 39():53. PubMed ID: 24011228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
    Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.